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ABSTRACT: Background: Parkinson’s disease
(PD) etiology is not well understood. Reported inverse
associations with smoking and coffee consumption
prompted the investigation of alcohol consumption as
a risk factor, for which evidence is inconclusive.
Objective: To assess the associations between alco-
hol consumption and PD risk.
Methods: Within NeuroEPIC4PD, a prospective
European population-based cohort, 694 incident PD
cases were ascertained from 209,998 PD-free partici-
pants. Average alcohol consumption at different time
points was self-reported at recruitment. Cox regres-
sion hazard ratios were estimated for alcohol con-
sumption and PD occurrence.
Results: No associations between baseline or lifetime
total alcohol consumption and PD risk were observed.
Men with moderate lifetime consumption (5–29.9
g/day) were at ~50% higher risk compared with light
consumption (0.1–4.9 g/day), but no linear exposure–
response trend was observed. Analyses by beverage
type also revealed no associations with PD.
Conclusion: Our data reinforce previous findings
from prospective studies showing no association
between alcohol consumption and PD risk. © 2020
The Authors. Movement Disorders published by
Wiley Periodicals, Inc. on behalf of International
Parkinson and Movement Disorder Society.
Key Words: alcohol; EPIC; epidemiology; Parkinson;
prospective cohort
The etiology of Parkinson’s disease (PD) is complex
and likely involves both genetic and environmental fac-
tors.1 There are strong and consistent observations that
cigarette smoking2-4 and coffee drinking4,5 are associ-
ated with a decreased risk of PD. Although the specific
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mechanisms are still poorly understood, these observed
associations are probably not explained by reverse cau-
sation or confounding.3-5
In addition to smoking and coffee consumption, alco-
hol consumption is another possible factor involved in
the development of PD. Several meta-analyses on the
association between alcohol consumption and the risk
of PD have been conducted, all suggesting an inverse
association.6,7 The results, however, are as yet inconclu-
sive: the inverse association was mainly observed in ret-
rospective case-control studies, but was not as clear in
studies based on prospective cohorts.
By design, case-control studies have some limitations.
First, these studies are prone to recall bias, as the dis-
ease status and disease characteristics may affect the
retrospective assessment of alcohol consumption habits.
Another risk is selection bias because controls may not
well reflect the source population. Finally, associations
observed in case-control studies may be the result of
reverse causality, for example, when premorbid changes
led to reduced alcohol consumption.
Few large prospective studies, largely avoiding these
biases, have been published on alcohol consumption
and PD risk. Three large-scale cohort studies, all con-
ducted in the United States, concluded that there is no
or only weak evidence for a decreased risk of PD in
association with total alcohol consumption.8-10 Specific
types of alcoholic beverages, however, were suggested
to have different effects: a lower PD risk was reported
for moderate beer drinkers,8,9 whereas liquor consump-
tion was associated with higher risk.8
Our objective was to assess the association between
alcohol consumption and the risk of PD in a large
European prospective cohort study. We present risk
estimates for average alcohol consumption 12 months
prior to the recruitment (short term) and during life-
time, that is, since the age of 20 years (long term), as
well as the PD risks associated with different types of
alcoholic beverages.
Methods
In the early 1990s, the European Prospective Investi-
gation into Cancer and Nutrition (EPIC) cohort study
has been established, with more than 521,000 partici-
pants.11 At recruitment, the participants were mainly
between 35 and 70 years old and lifestyle factors were
self-reported using validated questionnaires. Ethical
approval was obtained from the ethical committee
of the International Agency for Research on Cancer
and ethical review boards of each participating
center. All participants signed an informed consent.
NeuroEPIC4PD comprises a subset of 220,494 partici-
pants within EPIC, recruited in Germany, Greece,
Italy, the Netherlands, Spain, Sweden, and the United
Kingdom.12
TABLE 1. Demographics and alcohol consumption habits
among NeuroEPIC4PD participants with and without PD
Characteristic






Male 353, 51% 78,042, 37%
Female 341, 49% 131,262, 63%
Age at recruitment, mean (SD) 61.2 (8.2) 52.9 (9.9)
Age at diagnosis, mean (SD) 68.7 (7.9) –




Italy 64, 9.2% 40,111, 19%
Spain 105, 15% 24,852, 12%
United Kingdom 171, 25% 23,227, 11%
The Netherlands 13, 1.9% 16,814, 8.0%
Greece 92, 13% 25,762, 12%
Germany 50, 7.2% 25,389, 12%
Sweden 199, 29% 53,149, 25%
Alcohol consumption at recruitment
Nonconsumer 150, 22% 37,662, 18%
Total g/day, mean (5th–95th
percentile)
10 (0–47) 11 (0–47)
Beer g/day, mean (5th–95th
percentile)
2.2 (0–8.6) 2.4 (0–11)
Wine g/day, mean (5th–95th
percentile)
6.1 (0–31) 6.9 (0–35)
Fortified wine g/day, mean
(5th–95th percentile)
0.6 (0–3.0) 0.6 (0–3.3)
Spirits g/day, mean (5th–95th
percentile)
1.4 (0–7.8) 1.4 (0–7.1)
Average lifetime alcohol
consumptiona
Never consumer 48, 10% 18 192, 12%
Total g/day, mean (5th–95th
percentile)
16 (0.6–57) 16 (0.3-60)
Beer g/day, mean (5th–95th
percentile)
2.9 (0–13) 3.4 (0–17)
Wine g/day, mean (5th–95th
percentile)
9.3 (0–42) 8.9 (0–39)
Fortified wine g/day, mean
(5th–95th percentile)
0.8 (0–3.7) 0.8 (0–3.4)
Spirits g/day, mean (5th–95th
percentile)
3.1 (0–11) 3.1 (0–14)
Smoking status at recruitment
Never 395, 57% 100,080, 48%
Former 219, 32% 57,899, 28%
Current 80, 12% 51,325, 25%
Coffee consumption at recruitment
Nonconsumer 79, 11% 14,500, 6.9%
>0 to <100 mL/day 154, 22% 43,560, 21%
100 to <250 mL/day 182, 26% 53,750, 26%
250 to <500 mL/day 160, 23% 48,486, 23%
≥500 mL/day 119, 17% 49,008, 23%
aInformation on lifetime alcohol consumption was missing for 216 PD cases
and 59,585 participants without PD.
NeuroEPIC4PD, is the study on Parkinson’s disease case ascertainment in
the EPIC cohort; PD, Parkinson’s disease; SD, standard deviation.
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Case Ascertainment
In NeuroEPIC4PD, 881 PD cases have been identified
and their diagnosis has been validated through clinical
record review.12 We limited our analyses to 209,998
participants, including 694 incident PD cases, after
removing 34 cases without date of diagnosis, 122 preva-
lent cases, 212 participants with PD-like conditions, and
10,128 participants (including 31 PD cases) with missing
information on alcohol consumption or smoking status
at baseline.
Assessment of Alcohol Consumption
Average consumption of alcoholic beverages during
the 12-month period before recruitment and at ages
20, 30, 40, and 50 years was collected via validated
country-specific dietary and standardized lifestyle ques-
tionnaires. Alcohol consumption at each point in time
was derived from the consumption frequency of glasses
of beer, cider, wine, fortified wine, sweet liquor, or dis-
tilled spirit. Total alcohol intake was expressed as grams
per day (g/day) based on country-specific and sex-specific
standard glass volumes and beverage-specific ethanol
percentages derived from 24-hour dietary recalls con-
ducted in a 10% subsample of the EPIC cohort. A more
detailed description of the variables can be found else-
where.13 Information on lifetime alcohol was available
for 150,197 participants (including 478 incident PD
cases) because these data were not collected in Sweden
and Naples (Italy).
Alcohol consumption was categorized into <0.1 g/day
(at recruitment, nonconsumers; at lifetime, never con-
sumers), 0.1 to 4.9 g/day (reference category), 5.0 to 14.9
g/day, 15.0 to 29.9 g/day, 30.0 to 59.9 g/day, and ≥ 60
g/day. As per previous EPIC papers,14-16 we used light
consumers (0.1–4.9 g/day) as the reference category
because total abstainers may represent a highly selective
group. For lifetime consumption of specific types of alco-
holic beverages, including beer, wine, fortified wine, and
spirit/liquor, ≥15 g/day was the highest category.
Statistical Analyses
Cox regression models using age as the underlying
time variable were applied to investigate the effects of
alcohol consumption on the risk of PD. Models were
TABLE 2. Number of PD cases and hazard ratios by levels of alcohol consumption (g/day): consumption at recruitment,
average lifetime consumption, and average lifetime consumption per type of alcoholic beverage
Alcohol consumption
at recruitment (g/day)
All, n = 209,998
Men, n = 78,395 Women, n = 131,603
PD cases HRa (95% CI) PD cases HRa (95% CI) PD cases HRa (95% CI)
Nonconsumer 150 0.99 (0.80–1.24) 47 1.11 (0.77–1.60) 103 1.00 (0.76–1.32)
0.1–4.9 210 1.00 (ref ) 86 1.00 (ref ) 124 1.00 (ref )
5.0–14.9 174 0.95 (0.78–1.17) 91 1.01 (0.75–1.37) 83 0.96 (0.72–1.28)
15–29.9 95 1.03 (0.80–1.33) 69 1.12 (0.80–1.55) 26 1.09 (0.71–1.68)
30–59.9 53 1.05 (0.76–1.45) 48 1.22 (0.84–1.77) 5 0.85 (0.34–2.09)
≥60 12 0.69 (0.38–1.26) 12 0.81 (0.43–1.53) 0 –
P value for trendb 0.47 0.98 0.34
Average lifetime alcohol
consumption (g/day)
All, n = 150,197 Men, n = 54,633
Women, n = 95,564
PD cases HRa (95% CI) PD cases HRa (95% CI) PD cases HRa (95% CI)
Never consumer 48 0.91 (0.65–1.27) 8 1.29 (0.60–2.78) 40 0.79 (0.54–1.15)
0.1–4.9 146 1.00 (ref ) 40 1.00 (ref ) 106 1.00 (ref )
5.0–14.9 142 1.23 (0.97–1.57) 84 1.58 (1.07–2.33) 58 1.07 (0.77–1.48)
15–29.9 77 1.07 (0.78–1.45) 64 1.52 (1.00–2.33) 13 0.82 (0.46–1.49)
30–59.9 47 0.98 (0.67–1.43) 47 1.44 (0.91–2.28) 0 –
≥60 18 0.72 (0.43–1.23) 18 1.11 (0.61–2.03) 0 –
P value for trendb 0.10 0.55 0.16
Average lifetime alcohol
consumption (g/day)
Beer Wine Fortified wine Spirit/liquor
PD cases HRa (95% CI) PD cases HRa (95% CI) PD cases HRa (95% CI) PD cases HRa (95% CI)
Never consumer 177 0.94 (0.75–1.16) 103 0.95 (0.74–1.21) 251 0.79 (0.63–0.96) 220 1.16 (0.94–1.45)
0.1–4.9 234 1.00 202 1.00 211 1.00 194 1.00
5.0–14.9 48 0.94 (0.68–1.31) 87 1.15 (0.88–1.49) 13 0.97 (0.54–1.73) 49 0.99 (0.72–1.37)
≥15 19 0.85 (0.52–1.39) 86 0.94 (0.69–1.28) 3 0.91 (0.28–2.92) 15 0.72 (0.42–1.23)
P value for trend2 0.45 0.19 0.27 0.67
aHR, adjusted for age at recruitment, sex (in combined analyses), country, smoking status, and coffee consumption; and 95% CI.
bTrend among alcohol consumers only.
PD, Parkinson’s disease; HR, hazard ratio; CI, confidence interval; ref, reference.
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adjusted for sex, age at recruitment, country, smoking
status at recruitment (never, former, current smoker)
and average coffee consumption at recruitment (never,
>0–<100, 100–<250, 250–<500, >500 mL/day). We
also considered educational level as possible con-
founding factor, but this variable did not modify the
risk estimates (P > 0.1) and was therefore not included
in the final models. Although other environmental fac-
tors have been reported to affect PD risk,1 our data
did not allow for considering additional adjustments.
Models were run for both alcohol consumption at
recruitment and during lifetime and by type of alco-
holic beverage.
We stratified analyses by sex to assess possible differ-
ent associations among men and women.17 For sensitiv-
ity analyses, we stratified analyses by smoking status at
recruitment (ever vs. never smoker) because of its
strong inverse association with PD3 and its relation
with alcohol consumption. We also tested if there was
an interaction between smoking and alcohol consump-
tion. In addition, we ran analyses separately for PD
cases who were diagnosed within or after the mean of
8 years since recruitment to assess the possible effects
of changes due to early disease processes. To further
explore possible reverse causation as the explanation of
positive findings in previous case-control studies, we
also ran the same analyses on prevalent PD cases within
NeuroEPIC4PD (n = 92 with information on alcohol
consumption at recruitment).
Results
Demographic characteristics and alcohol consump-
tion for PD cases and participants without PD in the
NeuroEPIC4PD cohort are described in Table 1.
No association between alcohol consumption at
recruitment and the risk of PD was observed overall
nor when stratified by sex (Table 2). The average life-
time alcohol consumption also did not show an associa-
tion with PD risk overall. Analyses limited to men
showed increased risks for the lifetime moderate con-
sumers (hazard ratio = 1.58 [95% confidence interval,
1.07–2.33] for 5–14.9 g/day and hazard ratio = 1.52
[95% confidence interval, 1.00–2.33] for 15–29.9
g/day) compared with light consumers (0.1–4.9 g/day),
but there was no exposure–response trend (P = 0.55).
Analyses for lifetime consumption by type of alco-
holic beverage did not reveal any association with PD
risk (Table 2). Stratification by smoking indicated no
association between average lifetime alcohol consump-
tion and PD risk among never smokers (Supplemental
Table S1). Among ever smokers, there was a possible
decreasing risk of PD with increased average lifetime
alcohol consumption (Ptrend = 0.07). The P value for
interaction between lifetime average number of ciga-
rettes per day and alcohol consumption was 0.09.
Analyses separating PD cases diagnosed within or after
8 years of recruitment revealed comparable results (data
not shown). A negative exposure-response trend between
lifetime alcohol consumption and PD risk (P = 0.04) was
observed for prevalent cases (Supplemental Table S2).
Discussion
We observed no associations between baseline or life-
time alcohol consumption and the risk of PD in the
NeuroEPIC4PD cohort. These findings are consistent
with previous large prospective studies.8-10 Our ana-
lyses by type of alcoholic beverage (beer, wine, fortified
wine, spirit/liquor) also revealed no associations.
In contrast to smoking and coffee consumption, for
which inverse associations with PD risk have been con-
sistently reported by several groups across study
designs,3-5 prospective studies on alcohol point toward
no association. The observed inverse associations with
alcohol reported in PD case-control studies has been
suggested to be related to recall bias, reverse causation,
or residual confounding by smoking.9,10
Reverse causation can be the result of disease-related
changes in behavior, for example, when PD patients
were more prone to stop or reduce drinking because of
their symptoms.10 Patients may recall their previous
drinking habits differently because of these changes.
This possibility is supported by our sensitivity analyses
among prevalent PD cases, mimicking a case-control
study where cases are typically interviewed after diag-
nosis, which would have led to a different conclusion.
Although based on much fewer cases, a decreasing risk
of PD was observed with lifetime alcohol consumption
(Ptrend = 0.04). Because no association was observed
among incident cases, this points toward reverse causal-
ity in previous case-control studies rather than a true
inverse association.
Our stratified analyses by smoking status of incident
cases showed that analysis among ever smokers only
there was a suggestion of a protective effect of alcohol
(Ptrend = 0.07; Supplemental Table S1). This observa-
tion provides support for the hypothesis that residual
confounding by smoking may have played a role in pre-
vious reports on the association between alcohol
and PD.
Given the role of dopaminergic pathways in reward
mechanisms, it has been hypothesized that PD patients
might be less prone to addictive behaviors, either as a
consequence of dopamine shortage or because of their
genetic makeup.18 If alcohol consumption is indeed not
associated with PD, the repeatedly suggested role of
addictive behavior in predisposition to PD is not plausi-
ble, which offers further support to a true biological
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mechanism for components of cigarette smoke and cof-
fee consumption in PD etiology.
A major strength of our analyses is that we had access
to a large prospective cohort, with a mean follow-up of
12.4 years12 and with lifetime lifestyle data (including
alcohol consumption) collected at baseline. Furthermore,
all PD cases were clinically confirmed by neurologists
specialized in movement disorders,12 and by limiting our
main analyses to incident cases, we circumvented any
form of recall bias or reverse causation.
Observational studies on PD are complicated by the
long prodromal phase of 20 years or more that can
proceed the disease,1 although it is unclear if and how
the nonmotor symptoms in this phase would affect
alcohol consumption. Our stratified analyses by time to
diagnosis indicated no association in either stratum.
Some exposure misclassification possibly occurred
because we relied on self-reported drinking habits. How-
ever, this possiblemisclassificationwould be nondifferential
because we collected lifestyle information prospectively.
Moreover, previous analyses within the EPIC cohort inves-
tigating alcohol consumption and other health outcomes
have shown the information as of sufficient quality to
detect known associations with cardiovascular and can-
cer outcomes.14-16 Furthermore, a clear and robust
inverse association has been observed for smoking and
PD risk within the NeuroEPIC4PD cohort,3 and no dif-
ference in misclassification between smoking and drink-
ing habits is expected.
Different effects per beverage type have been suggested
by some studies,8,9 but not ours. Although our observa-
tions are in line with Palacios and colleagues,10 we might
have missed possible effects for specific beverages as a
result of exposure misclassification.
Alcohol consumption varied between countries
(Supplemental Table S3), but a heterogeneity test
(P = 0.71) indicated that associations between alcohol
and PD risk were not different across countries. For
part of the cohort, we had no data on lifetime alcohol
consumption, which information was not available for
Sweden and Naples (Italy). However, because there was
no heterogeneity in effects between countries, these
missing data will not have affected our findings.
Overall, our data support previous findings from
large U.S. prospective studies that there is no associa-
tion between alcohol consumption and the risk of PD.
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ABSTRACT: Background: If mild parkinsonian
signs can be a marker for Parkinson’s disease (PD)
development, an impaired Timed Up and Go test
(TUG) should also be a marker for prodromal PD.
Objectives: To investigate whether the Timed Up and
Go test is associated with PD.
Methods: We included 1,196,614 participants at
66 years of age who underwent the National Screen-
ing Program for Transitional Ages for Koreans
between 2009 and 2014. Timed Up and Go test times
were classified into <10 and ≥10 seconds. Incidence
of PD was defined using claims data.
Results: During the median follow-up period of
3.5 years, participants with slow Timed Up and Go
test time had significantly increased risk of developing
PD compared with those with normal Timed Up and
Go test time (adjusted hazard ratio: 1.28; 95% confi-
dence interval: 1.20–1.37). Furthermore, participants
with an abnormal Timed Up and Go test result,
defined as ≥20 seconds, had a significantly increased
risk of PD compared with those with a normal Timed
Up and Go test result (adjusted hazard ratio: 2.18;
95% confidence interval: 1.63–2.92).
Conclusion: An indicator of subtle motor deficits, the
Timed Up and Go test could be a prodromal marker
for the risk of PD development. © 2020 International
Parkinson and Movement Disorder Society
Key Words: mild parkinsonian signs; Parkinson’s
disease; prodromal Parkinson’s disease; Timed Up and
Go test
Parkinson’s disease (PD) is identified by clinical diag-
nostic criteria that encompass various motor symptoms.1
Slight motor deficits precede clinical PD in prodromal
PD patients and are very mild and therefore insufficient
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